Gattai, Minoli, Agostinelli & Partners advised Intermediate Capital Group’s Europe VII Fund in the acquisition, in partnership with Mérieux Equity Partners together with the management team, of DOC Generici, one of the largest independent Italian pharmaceutical companies. The deal is subject to the approval by the competent antitrust authorities and has a value of Euro 1.1 billion.
DOC Generici commercialises medicines to treat medical conditions through a broad portfolio of products and a presence in several areas which include cardiovascular, gastrointestinal and neurological treatments.
This is the seventh investment by Europe VII Fund that provides long term financing to private companies having growth potential in Europe. The Fund has collected commitments for Euro 4.5 billion in November 2018.
The Gattai, Minoli, Agostinelli & Partners team was formed, for the corporate aspects, by Partners Bruno Gattai and Gerardo Gabrielli, by Counsel Lorenzo Fabbrini and by Associate Maria Persichetti. For the finance aspects, by Partners Riccardo Agostinelli, Marco Leonardi and Lorenzo Vernetti and by Associate Daniele Migliarucci. For the tax aspects, by Partner Cristiano Garbarini and Associates Alban Zaimaj and Valentina Buzzi. The team was completed, for the administrative aspects, by Of Counsel Micaela Tinti, for the antitrust aspects by Partner Silvia D’Alberti and by Associates Fabiana Campopiano and Angela Gagliardi, for the for the IP aspects by Partner Licia Garotti and Associate Vittoria Omarchi and, finally, for the labour aspects, by Partner Lorenzo Cairo and Associate Federica Ferretti.